Given that down regulation of AnxA6 in invasive breast cancer cells was accompanied by a decrease in the total and activated EGFR in invasive breast cancer cells, we speculated that AnxA6-depletion in these cells might affect their response to EGFR-targeted TKIs. This evidence concerns the gene EGFR and invasive breast carcinoma.